Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
274.25
+8.39 (3.16%)
May 12, 2025, 2:30 PM - Market open
Amgen Revenue
Amgen had revenue of $8.15B in the quarter ending March 31, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $34.13B, up 15.56% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$34.13B
Revenue Growth
+15.56%
P/S Ratio
4.19
Revenue / Employee
n/a
Employees
n/a
Market Cap
147.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
AMGN News
- 2 hours ago - Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet - Seeking Alpha
- 2 days ago - AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE - PRNewsWire
- 4 days ago - Amgen CEO Robert A. Bradway to Receive Honorary Degree from KGI - GlobeNewsWire
- 5 days ago - Amgen's TEPEZZA®▼ (teprotumumab) Granted Marketing Authorisation as the First Targeted Treatment Specifically for Adults With Moderate-to-severe Thyroid Eye Disease (TED) in the United Kingdom - Business Wire
- 6 days ago - Amgen: Waiting Patiently For A Real Catalyst - Seeking Alpha
- 8 days ago - Amgen: Reducing My Price Target, Reiterate Buy After A Solid Q1 - Seeking Alpha
- 9 days ago - Dogs Of The Dow Chase May's 'Safer' Buy - Seeking Alpha
- 10 days ago - Amgen Inc. (AMGN) Q1 2025 Earnings Call Transcript - Seeking Alpha